# Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

> **NCT01697579** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 240 (actual)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Fosaprepitant
- **DRUG:** Fosaprepitant Placebo
- **DRUG:** Ondansetron
- **DRUG:** 5-hydroxytryptamine 3 antagonist

## Key facts

- **NCT ID:** NCT01697579
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-13
- **Primary completion:** 2016-11-21
- **Final completion:** 2016-11-21
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01697579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01697579, "Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01697579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*